The effects of 6-month therapy using a standardized composition of bergamot polyphenols in a patient with mild dyslipidemia Case report
Article Sidebar
Main Article Content
Abstract
Lipid disorders are one of the most important modifiable cardiovascular risk factors. Treatment of dyslipidemia is one of the key elements of both primary and secondary prevention of CVD.
In the group of patients with low cardiovascular risk and a only slightly elevated cholesterol concentration, the recommended action is healthy lifestyle modification. However, in real life, a significant part of patients have difficulty implementing that recommendations. In such group of patients, the solution may be the use of specific dietary supplements with proven clinical effectiveness – such as monacoline or BPF.
This clinical case illustrates the possibilities of BPF treatment in a young woman with mild lipid disorders.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Piepoli M., Hoes A., Agewall S. et al.: 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2016; 37(29): 2315-2381.
3. Szymański F.M., Barylski M., Cybulska B.: Rekomendacje dotyczące leczenia dyslipidemii w Polsce – III Deklaracja Sopocka. Interdyscyplinarne stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Choroby Serca i Naczyń 2018; 15(4): 199-210.
4. Barylski M., Filipiak K.J., Okopień B.: Stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego dotyczące miejsca standaryzowanej kompozycji polifenoli z bergamoty w terapii dyslipidemii oraz jej innego potencjalnego zastosowania w praktyce klinicznej. Folia Cardiologica 2018; 13(3): 222-235.
5. Mollace V., Sacco I., Janda E. et al.: Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 2011; 82(3): 309-316.
6. Gliozzi M., Carresi C., Musolino V.: The effect of bergamot-derived polyphenolic fraction on LDL small dense particles and non-alcoholic fatty liver disease in patients with metabolic syndrome. Adv. Biol. Chem. 2014; 4: 129-137.